Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he was at Millennium Pharmaceuticals, Inc., before Millennium, he held scientific and business roles at Biogen, Inc. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Sciences. He is also member of the Board of Directors for Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, ProKidney Corp., Takeda Pharmaceuticals, Aerium, Hemab, Aera, and Versanis, and the Biotechnology Innovation Organization. In addition, he serves on the Board of the Termeer Foundation and as Chair of the n-Lorem Foundation Advisory Council on the Advisory Board of Ariadne Labs and as an advisor to Nucleate.
Yael Weiss, Mahzi
Peter Marks, FDA